Biotech startup Keylika has launched NistuHeal™, a steroid-free, medicated skin cream formulated to provide relief from eczema, in India, with plans to expand to the United States. 30 million people in the United States suffer from at least one form of eczema, affecting roughly 10% of the population.
To address the lack of effective, steroid-free, natural treatments for eczema, particularly mild-to-moderate cases, Keylika co-founders Dr. Buddha Chaudhuri and Dr. Frederik Ceyssens developed NistuHeal. NistuHeal, originally developed in the U.S., is now available over-the-counter in India through e-commerce platforms.
Chaudhuri, Keylika’s CEO, was inspired to create NistuHeal based on his personal struggles with eczema. “For over a decade I battled frustrating eczema flare-ups and the perpetual itch-scratch cycle,” said Chaudhuri. “The standard topical steroid treatments only provided temporary relief before the uncontrollable itch would return. I knew there had to be a better solution.”
Drawing on their combined 30+ years of expertise in drug delivery and biotechnology, Chaudhuri and Ceyssens carefully selected 11 plant-based active ingredients known to benefit eczematous skin. NistuHeal’s proprietary blend includes hydrolyzed colloidal oatmeal, zinc and magnesium complexes, amino acids and botanical extracts chosen for their anti-inflammatory, anti-itch, antimicrobial, and wound healing properties.
After extensive in-house testing and iterations, Chaudhuri managed the complex regulatory process to register NistuHeal as an over-the-counter drug in India. Local partner Streem Bio oversaw cGMP-compliant manufacturing and launched sales and marketing efforts.
“The response from dermatologists has been tremendous,” said Chaudhuri. “Clinicians recognize the need for a natural, steroid-free alternative for mild-to-moderate eczema.” To validate NistuHeal’s safety and efficacy, Keylika conducted a 28-day clinical study on patients with mild-to-moderate atopic dermatitis. Results demonstrated that NistuHeal significantly reduced eczema symptoms and itching, with over half of subjects reporting major improvements in their skin conditions, without any adverse side effects.
NistuHeal’s successful launch in India has proven there is strong demand for effective natural eczema therapies in the over-the-counter market. Keylika plans to expand availability to other regions in the coming months, starting with the U.S.
About Keylika
Keylika is a young biotechnology startup developing innovative medicines using cutting edge drug delivery systems. The company, based out of the San Francisco Bay Area, was accepted into Y Combinator, S22 cohort and won a Golden Ticket at MBC BioLabs sponsored by Nitto Denko. Keylika employs 30+ years of research experience across top universities to engineer drug delivery solutions for enhanced drug efficacy and safety. Learn more at www.keylika.com.
Media Contact
Organization: Keylika
Contact Person: Buddhadev Chaudhuri
Website: https://www.keylika.com/
Email: info@keylika.com
City: San Francisco
State: CA
Country: United States
Release Id: 2810237395